Results From Phase 3 XGEVA ® (Denosumab) Study In Patients With Multiple Myeloma Published In The Lancet Oncology

In this study, XGEVA successfully met the primary endpoint, demonstrating non-inferiority to zoledronic acid in delaying the time to first on-study skeleta...
Source: Amgen News Release - Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Related Links:

Conclusion: Linc00515 enhanced autophagy and chemoresistance of melphalan-resistant myeloma by directly inhibiting miR-140-5p, which elevatedATG14 level.Cell Physiol Biochem 2018;48:2517 –2527
Source: Cellular Physiology and Biochemistry - Category: Cytology Source Type: research
AbstractIt is well established that some rheumatic syndromes (RS) are associated with several hematological malignancies. We aimed to describe the clinical course of patients with hematological malignancies mimicking RS. We studied a series of four patients presenting with apparent RS who were eventually diagnosed with hematological malignancies, and reviewed the relevant literature. Our series consisted of 4 patients, with a mean age of 62.8  ± 20.3 years, who presented to our rheumatology unit between December 2012 and March 2018. Two patients were initially diagnosed with polyarthritis. One of these...
Source: Rheumatology International - Category: Rheumatology Source Type: research
This study supports the beneficial effects of simvastatin on multiple myeloma serum-induced endothelial haemostatic imbalance, which suggests that simvastatin may serve as a new and appropriate antithrombotic approach for multiple myeloma patients.
Source: Blood Coagulation and Fibrinolysis - Category: Hematology Tags: Original Articles Source Type: research
Though survival rates have improved markedly, a variety of problems can cause death.
Source: NYT Health - Category: Consumer Health News Authors: Tags: Leukemia Antibiotics Cancer Multiple Myeloma Bone Marrow Deaths (Fatalities) Longevity Infections Heart Source Type: news
AbstractIxazomib, the first oral proteasome inhibitor, is approved in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma (MM) who have received at least one prior therapy. Ixazomib is a selective, potent, and reversible inhibitor of the 20S proteasome, and preferentially binds to and inhibits the β5 chymotrypsin-like proteolytic site. Ixazomib absorption is rapid, with a median time to reach maximum plasma concentration of approximately 1 h post-dose. Ixazomib pharmacokinetics (PK) are adequately described by a three-compartment model (terminal half-life of 9.5&nbs...
Source: Clinical Pharmacokinetics - Category: Drugs & Pharmacology Source Type: research
miR-22 suppresses DNA ligase III addiction in multiple myeloma, Published online: 17 August 2018; doi:10.1038/s41375-018-0238-2miR-22 suppresses DNA ligase III addiction in multiple myeloma
Source: Leukemia - Category: Hematology Authors: Source Type: research
Whole-body MR imaging (WB-MR imaging) has become a modality of choice for detecting bone metastases in multiple cancers, and bone marrow involvement by multiple myeloma or lymphoma. Combination of anatomic and functional sequences imparts an inherently hybrid dimension to this nonirradiating tool and extends the screening of malignancies outside the skeleton. WB-MR imaging outperforms bone scintigraphy and CT and offers an alternative to PET in many tumors by time of lesion detection and assessment of treatment response. Much work has been done to standardize procedures, optimize sequences, validate indications, confirm pr...
Source: PET Clinics - Category: Radiology Authors: Source Type: research
This study aimed to analyze the treatment efficacy of ASCT in a Taiwanese cohort and evaluate possible prognostic factors.MethodsFrom the database of the Taiwan Blood and Marrow Transplantation registry, data on 396 patients with MM who underwent ASCT were reviewed.ResultsThe average age of participants was 54.8 years, and there were more men than women (57.6% vs. 42.4%). Most patients were diagnosed with IgG-type myeloma (52.4%), followed by IgA-type (23.2%) and light-chain type (21.4%). Patients with Durie Salmon Staging System (DSS) III disease accounted for 61.9% of the study cohort, while 23.7% had stage II and 14.4% ...
Source: Journal of the Formosan Medical Association - Category: General Medicine Source Type: research
A 62-year-old female presenting with anemia and extensive hemorrhages is reported. Coagulation tests showed significantly prolonged prothrombin time (PT) and activated partial thromboplastin time. Decreased levels of clotting factor X activity were determined (5.4%). Bone marrow biopsy revealed neoplastic plasma cells. Serum and urine protein electrophoresis were both negative for monoclonal gammopathy, and both bone marrow and abdominal fat biopsies were negative for amyloid deposition. The patient was diagnosed as suffering from nonsecretory multiple myeloma (MM) complicated by acquired factor X deficiency. A complete re...
Source: Acta Haematologica - Category: Hematology Source Type: research
Condition:   Multiple Myeloma Interventions:   Drug: Nivolumab 240mg;   Radiation: Radiation therapy Sponsor:   Weill Medical College of Cornell University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer & Oncology | Myeloma | Pharmaceuticals | Reclast | Study | Xgeva | Zometa